m. tuberculosis h37rv

BM635 hydrochloride is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 mesylate is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

GSK2200150A 是一种通过高通量筛选活动确定的抗结核剂，对 H37Rv 的 MIC 是 0.38 μM。

BM212 是一种分枝杆菌膜蛋白 MmpL3抑制剂。它抑制结核分枝杆菌和部分非结核分枝杆菌，抗结核杆菌 H37Rv 菌株的 MIC 值为 5 µM。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

Antituberculosis agent-7 是一种氧杂环丁基喹啉衍生物，对P. mirabilis 具有良好的抗菌活性，MIC 为 31.25 μM。Antituberculosis agent-7 对A. niger 显示出良好的抗真菌活性，MIC 为 62.5 μM。Antituberculosis agent-7 显示出优异的抗分枝杆菌活性，对结核分枝杆菌 H37Rv 的 MIC 为 3.41 μM。

sCNH240(2-Fluoro-N-[3-(3-thienyl)-5-isoxazolyl]benzenesulfonamide)是一种潜在的选择性 Rv1625c Cya 激活剂，具有良好的细胞渗透性和口服活性，在胆固醇补充的7H12培养基中对结核分枝杆菌（Mtb）H37Rv 株的IC90=1.24 µM，对 CYP2C19，CYP2C9 和hERG 通道具有抑制作用。

Pks13-IN-1 (Compound 44) 是一种口服有效的 Mycobacterium tuberculosis 聚酮合酶 13 (Pks13) 抑制剂。它对结核分枝杆菌 H37Rv 菌株的抑制浓度 (MIC) 为 0.07 μM。在小鼠模型中，Pks13-IN-1 展示了抗菌活性。

Polyketide synthase 13-IN-3 (compound 41) is a potent inhibitor of polyketide synthase 13, demonstrating a minimum inhibitory concentration (MIC) range of 0.0625-0.125 μg mL against the M. tuberculosis strain H37Rv.

Antituberculosis agent-8 是一种抗结核剂，对M. tuberculosis H37Rv 的 MIC 值为 3.53 μM (1.6 μg mL)。Antituberculosis agent-8 对A. niger 也显示出良好的抗真菌 (antifungal) 活性，MIC 为 62.50 μM。

MtInhA-IN-1是一种口服活性的选择性结核分枝杆菌NADH依赖性烯酰基载体蛋白还原酶(MtInhA)抑制剂，IC50值为0.23 μM。对结核分枝杆菌H37Rv菌株，其MIC为0.4 μM。

Antitubercular agent-17 (Compound 8a) 是一种抗结核剂，对 M. tuberculosisH37Rv、Spec. 192、Spec 210 和 Spec. 800 的 MIC 值分别为 2、2、2 和 128 μg ml。Antitubercular agent-17 表现出高选择性的抗分支杆菌效果。

Antituberculosis agent-2 (Compound 8d) 是一种针对耐多药结核病和药物敏感结核病均有效的抗结核剂。Antituberculosis agent-2 在小鼠和人类中显示出良好的微粒稳定性，具有低细胞毒性和可接受的口服生物利用度。Antituberculosis agent-2 具有抗结核活性。Antituberculosis agent-2 对结核分枝杆菌 H37Rv、13946 和 14862 的 MIC 值分别为0.454、1.757 和 1.644 μg mL。

Antitubercular agent-23 是有效的抗念珠菌及抗结核剂，能够作用于 Candida albicansMTCC 3017 (MIC: 1.1 μg ml) 和 M. tuberculosis(H37Rv) (MIC: 1 μg ml)。

Antitubercular agent-25 (Compound 28) 是一种抗结核剂。Antitubercular agent-25抑制细胞外M. tuberculosisH37Rv 的IC50为 0.42 μM，细胞内为 0.20 μM。Antitubercular agent-25代谢稳定性良好。

Antitubercular agent-18 (Compound 9a) 为抗结核剂，对M. tuberculosisH37Rv、Spec. 192、Spec 210 及 Spec. 800 的最小抑制浓度(MIC)值依次为2、2、2 及128 μg ml，展现出对分支杆菌的高选择性抗菌活性。

Antituberculosis agent-1 (Compound 8a) 是一种抗结核剂，对 M. tuberculosisH37Rv 的 MIC 值为 3.84 μg mL。

Antibacterial agent 118 (also known as compound 20) is a potent antimycobacterial compound with activity against various mycobacterial strains, including Mtb H37Ra, M. aurum, M. smegmatis, Mtb H37Rv, and M. avium. The minimum inhibitory concentration (MIC) values for Antibacterial agent 118 against these strains are 40.7 μM, 10.2 μM, 163.0 μM, 62.5 μM, and 62.5 μM, respectively. This compound holds potential for tuberculosis research [1].

Antitubercular agent-21 (Compound 15) 是具有低细胞毒性的抗结核剂。Antitubercular agent-21 对 M. tuberculosisH37Rv 的 MIC 值为 0.4 μg mL。然而，Antitubercular agent-21 对其他微生物，如革兰氏阳性菌、革兰氏阴性菌或真菌，表现出较低的生物活性。

Antitubercular agent-16 (Compound 5q) is a potent antitubercular agent exhibiting high efficacy against various strains of M. tuberculosis, including H37Rv, CF16, CF61, CF76, CF152, and CF161, with MIC 90 values ranging from 0.40 to 23.51 μg mL. Notably, Antitubercular agent-16 demonstrates minimal cytotoxicity towards macrophages and pulmonary fibroblasts, further highlighting its potential as a therapeutic agent [1].

Tuberculosis inhibitor 3 (compound 2i)是一种高效和具有口服生物利用度的抗结核药物，对药敏和耐药结核分枝杆菌，M. tuberculosis H37RV与MDR-TB，体外抗药活性均为MIC < 0.016 μg mL。

PknB-IN-1 (Compound 2) is an inhibitor of protein kinase B (PknB) with a concentration causing 50% inhibition (IC50) of 14.4 μM. This compound demonstrates anti-mycobacterial activity by effectively suppressing the growth of M. tuberculosis H37Rv strain, with a minimum inhibitory concentration (MIC) of 6.2 μg mL [1].

Antitubercular agent-26 (Compound 32) 是一种口服具有活力的抗结核剂，能够作用于 M. tuberculosisH37Rv 细胞（在细胞外的 IC50: 0.50 μM，细胞内的 IC50: 0.51 μM)。Antitubercular agent-26 具有良好的代谢稳定性，及低心脏毒性风险低，没有遗传毒性。